- Center on Health Equity and Access
- Clinical
- Health Care Cost
- Health Care Delivery
- Insurance
- Policy
- Technology
- Value-Based Care
25% of Patients Prescribed Opioids End Up Using the Drugs Long Term
Nearly one-fourth of patients with an opioid prescription for use for chronic pain will end up using the drugs in the long term, according to the result of a new study published in Mayo Clinic Proceedings.
Nearly one-fourth of patients with an opioid prescription for use for chronic pain will end up using the drugs in the long term, according to the result of a new study published in Mayo Clinic Proceedings.
The Mayo Clinic researchers randomly selected 293 patients who had a new prescription for opioids in 2009 and tracked patterns over the next 12 months. During the time studied, 515 new opioid prescriptions were written for the patients. The study found that 61 patients (21%) progressed from short-term to episodic use while 19 patients (6%) omoved to long-term use (lasting more than 4 months).
Read more at MD Magazine: http://bit.ly/1dGrGob
How Can Digital Care Programs Aid Those With Chronic Musculoskeletal Pain?
June 9th 2020On this episode of Managed Care Cast, we speak with Jeffrey Krauss, MD, chief medical officer of Hinge Health and Stanford Clinical assistant professor, about the efficacy of a 12-week digital care program aimed to reduce lower back and knee pain in a real-world population.
Listen
Understanding the Impact of Inappropriate Opioid Prescribing Practices
April 19th 2019Deaths from drug overdoses have become the leading cause of death for Americans under age 50, which can largely be attributed to prescription opioids. Due to the role of prescription opioids, understanding prescribing patterns and identifying inappropriate prescribing are crucial for changing the course of the epidemic.
Listen
MBSR Reduced Pain Perception in Patients With Migraine
December 19th 2020The finding about mindfulness-based stress reduction (MBSR) was a secondary outcome of the double-blinded, randomized, placebo-controlled clinical trial. The primary outcome—a reduction in the frequency of migraines—was not reached.
Read More
